These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24713902)

  • 21. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients.
    Wener KM; Schechner V; Gold HS; Wright SB; Carmeli Y
    Antimicrob Agents Chemother; 2010 May; 54(5):2010-6. PubMed ID: 20211888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: emergence of high resistance against cefepime, the fourth generation cephalosporin.
    Grover SS; Sharma M; Chattopadhya D; Kapoor H; Pasha ST; Singh G
    J Infect; 2006 Oct; 53(4):279-88. PubMed ID: 16488476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective analysis of clinical and microbiological aspects of Klebsiella oxytoca bacteremia over a 10-year period.
    Kim BN; Ryu J; Kim YS; Woo JH
    Eur J Clin Microbiol Infect Dis; 2002 Jun; 21(6):419-26. PubMed ID: 12111596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals.
    Ensor VM; Shahid M; Evans JT; Hawkey PM
    J Antimicrob Chemother; 2006 Dec; 58(6):1260-3. PubMed ID: 17071956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and characterization of extended-spectrum beta-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals.
    Villegas MV; Correa A; Perez F; Miranda MC; Zuluaga T; Quinn JP;
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):217-22. PubMed ID: 15246513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bile bacterial flora and its in vitro resistance pattern in patients with acute cholangitis resulting from choledocholithiasis.
    Karpel E; Madej A; Bułdak Ł; Duława-Bułdak A; Nowakowska-Duława E; Łabuzek K; Haberka M; Stojko R; Okopień B
    Scand J Gastroenterol; 2011 Jul; 46(7-8):925-30. PubMed ID: 21504380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
    Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
    J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
    Zarakolu P; Metan G; Hasçelik G; Akova M
    Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of extended-spectrum cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolates from horses.
    Vo AT; van Duijkeren E; Fluit AC; Gaastra W
    Vet Microbiol; 2007 Oct; 124(3-4):248-55. PubMed ID: 17521833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival in the environment is a possible key factor for the expansion of Escherichia coli strains producing extended-spectrum β-lactamases.
    Starlander G; Yin H; Edquist P; Melhus Å
    APMIS; 2014 Jan; 122(1):59-67. PubMed ID: 23755901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
    Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence, molecular characterization, and phenotypic confirmation of extended-spectrum beta-lactamases in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca at the Radboud University Nijmegen Medical Centre in The Netherlands.
    Sturm PD; Bochum ET; van Mook-Vermulst SV; Handgraaf C; Klaassen T; Melchers WJ
    Microb Drug Resist; 2010 Mar; 16(1):55-60. PubMed ID: 20001741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Phenotypic and molecular identification of extended-spectrum beta-lactamase (ESBL) TEM and SHV produced by clinical isolates Escherichia coli and Klebsiella spp. in hospitals].
    González Mesa L; Ramos Morí A; Nadal Becerra L; Morffi Figueroa J; Hernández Robledo E; Alvarez AB; Marchena Bequer JJ; González Alemán M; Villain Plous C
    Rev Cubana Med Trop; 2007; 59(1):52-8. PubMed ID: 23427419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
    Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
    Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of broad spectrum beta-lactamases on in vitro sensitivity of clinical isolates of Klebsiella pneumoniae to oral cephalosporins].
    Bedenić B; Singer S
    Lijec Vjesn; 2000; 122(1-2):8-13. PubMed ID: 10916350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CTX-M and SHV-12 beta-lactamases are the most common extended-spectrum enzymes in clinical isolates of Escherichia coli and Klebsiella pneumoniae collected from 3 university hospitals within Korea.
    Kim J; Lim YM; Rheem I; Lee Y; Lee JC; Seol SY; Lee YC; Cho DT
    FEMS Microbiol Lett; 2005 Apr; 245(1):93-8. PubMed ID: 15796985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.